PB -> SA

Safeguarding public health

MHRA

17 FEB 2009

Dr P Bath
UNIVERSITY OF NOTTINGHAM
CLINICAL SCIENCES BUILDING
CITY HOSIPTAL
NOTTINGHAM
NG5 1PB
UNITED KINGDOM

16/02/2009

Dear Dr P Bath

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our reference:	03057/0033/001-0001
Eudract Number:	2007-004766-40
Product:	NITRO-DUR 0.2MG/H (5MG/24H) TRANSDERMAL PATCH
Protocol number:	30592

NOTICE OF ACCEPTANCE

I am writing to inform you that the Licensing Authority accepts your request for a clinical trial authorisation (CTA), received on 21/01/2009.

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

Finally, you are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed.

Yours sincerely,

Clinical Trials Unit
MHRA